loadpatents
name:-0.035030126571655
name:-0.020282030105591
name:-0.020752191543579
Haberkorn; Uwe Patent Filings

Haberkorn; Uwe

Patent Applications and Registrations

Patent applications and USPTO patent grants for Haberkorn; Uwe.The latest application filed is for "prostate specific membrane antigen (psma) ligands with improved tissue specificity".

Company Profile
21.21.33
  • Haberkorn; Uwe - Schwetzingen DE
  • Haberkorn; Uwe - Schweitzingen N/A DE
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Double-labeled probe for molecular imaging and use thereof
Grant 11,452,786 - Eder , et al. September 27, 2
2022-09-27
Prostate Specific Membrane Antigen (psma) Ligands With Improved Tissue Specificity
App 20220118121 - Eder; Matthias ;   et al.
2022-04-21
Labeled Inhibitors Of Prostate Specific Membrane Antigen (psma), Their Use As Imaging Agents And Pharmaceutical Agents For The Treatment Of Psma-expressing Cancers
App 20210393809 - HABERKORN; Uwe ;   et al.
2021-12-23
Double-labeled probe for molecular imaging and use thereof
Grant 11,020,493 - Eder , et al. June 1, 2
2021-06-01
Treatment of PMSA expressing cancers
Grant 10,980,901 - Morgenstern , et al. April 20, 2
2021-04-20
18f - Tagged Inhibitors Of Prostate Specific Membrane Antigen (psma) And Their Use As Imaging Agents For Prostate Cancer
App 20210053922 - CARDINALE; Jens ;   et al.
2021-02-25
Fap Inhibitor
App 20210038749 - HABERKORN; Uwe ;   et al.
2021-02-11
A Double-labeled Probe For Molecular Imaging And Use Thereof
App 20200368374 - EDER; Ann-Christin ;   et al.
2020-11-26
A Double-labeled Probe For Molecular Imaging And Use Thereof
App 20200353109 - EDER; Matthias ;   et al.
2020-11-12
18F--tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
Grant 10,815,200 - Cardinale , et al. October 27, 2
2020-10-27
Cd44v6-derived Cyclic Peptides For Treating Cancers And Angiogenesis Related Diseases
App 20200283503 - MATZKE-OGI; Alexandra ;   et al.
2020-09-10
CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
Grant 10,703,796 - Matzke-Ogi , et al.
2020-07-07
Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules
Grant 10,653,796 - Uhl , et al.
2020-05-19
Polypeptide With Tumour Binding Activity
App 20200131227 - HABERKORN; Uwe ;   et al.
2020-04-30
Treatment Of Pmsa Expressing Cancers
App 20200016281 - MORGENSTERN; Alfred ;   et al.
2020-01-16
Hydrophobic modified peptides and their use for liver specific targeting
Grant 10,513,539 - Mier , et al. Dec
2019-12-24
Labeled Inhibitors Of Prostate Specific Membrane Antigen (psma), Their Use As Imaging Agents And Pharmaceutical Agents For The T
App 20190374660 - EDER; Matthias ;   et al.
2019-12-12
Double-labeled Probe For Molecular Imaging And Use Thereof
App 20190365931 - Eder; Matthias ;   et al.
2019-12-05
Coating of Nanoparticle Surfaces with Cyclopeptides for Improving Delivery of Agents Via the Oral Route
App 20190351069 - Uhl; Philipp ;   et al.
2019-11-21
Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Grant 10,471,160 - Eder , et al. Nov
2019-11-12
Labeled Inhibitors Of Prostate Specific Membrane Antigen (psma), Their Use As Imaging Agents And Pharmaceutical Agents For The T
App 20190336622 - EDER; Matthias ;   et al.
2019-11-07
Conjugates for protection from nephrotoxic active substances
Grant 10,413,614 - Kuebelbeck , et al. Sept
2019-09-17
Double-labeled probe for molecular imaging and use thereof
Grant 10,406,246 - Eder , et al. Sept
2019-09-10
Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Grant 10,398,791 - Eder , et al. Sep
2019-09-03
Hydrophobic modified peptides for liver specific diagnosis
Grant 10,363,323 - Mier , et al.
2019-07-30
Conjugates of proteins and multivalent cell-penetrating peptides and their uses
Grant 10,253,099 - Strieker , et al.
2019-04-09
Labeled Inhibitors Of Prostate Specific Membrane Antigen (psma), Their Use As Imaging Agents And Pharmaceutical Agents For The Treatment Of Prostate Cancer
App 20190060491 - EDER; Matthias ;   et al.
2019-02-28
Labeled Inhibitors Of Prostate Specific Membrane Antigen (psma), Their Use As Imaging Agents And Pharmaceutical Agents For The Treatment Of Prostate Cancer
App 20190008988 - EDER; Matthias ;   et al.
2019-01-10
Liposomes Containing Cell Penetrating Peptides and Tetraetherlipids for the Oral Delivery of Macromolecules
App 20180303956 - Uhl; Philipp ;   et al.
2018-10-25
18f - Tagged Inhibitors Of Prostate Specific Membrane Antigen (psma) And Their Use As Imaging Agents For Prostate Cancer
App 20180194729 - CARDINALE; Jens ;   et al.
2018-07-12
18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Grant 10,016,519 - Kopka , et al. July 10, 2
2018-07-10
Conjugates For Protection From Nephrotoxic Active Substances
App 20180015173 - KUEBELBECK; Armin ;   et al.
2018-01-18
Hydrophobic modified pres-derived peptides of hepatitis B virus (HBV) and their use as vehicles for the specific delivery of compounds to the liver
Grant 9,868,768 - Mier , et al. January 16, 2
2018-01-16
Cd44v6-derived Cyclic Peptides For Treating Cancers And Angiogenesis Related Diseases
App 20170320930 - MATZKE-OGI; Alexandra ;   et al.
2017-11-09
Conjugates for protection from nephrotoxic active substances
Grant 9,808,535 - Kuebelbeck , et al. November 7, 2
2017-11-07
18f-tagged Inhibitors Of Prostate Specific Membrane Antigen (psma), Their Use As Imaging Agents And Pharmaceutical Agents For The Treatment Of Prostate Cancer
App 20170246327 - KOPKA; Klaus ;   et al.
2017-08-31
Labeled Inhibitors Of Prostate Specific Membrane Antigen (psma), Their Use As Imaging Agents And Pharmaceutical Agents For The Treatment Of Prostate Cancer
App 20160228587 - EDER; Matthias ;   et al.
2016-08-11
Conjugates For Protection From Nephrotoxic Active Substances
App 20160114054 - KUEBELBECK; Armin ;   et al.
2016-04-28
Conjugates of Proteins and Multivalent Cell-Penetrating Peptides and Their Uses
App 20150297742 - STRIEKER; Matthias ;   et al.
2015-10-22
.epsilon.-Polylysine conjugates and the use thereof
Grant 9,078,929 - Kuebelbeck , et al. July 14, 2
2015-07-14
Double-Labeled Probe for Molecular Imaging and Use Thereof
App 20150110715 - Eder; Matthias ;   et al.
2015-04-23
Hydrophobic Modified Peptides For Liver Specific Diagnosis
App 20140356284 - Mier; Walter ;   et al.
2014-12-04
Hydrophobic Modified Peptides And Their Use For Liver Specific Targeting
App 20140038886 - Mier; Walter ;   et al.
2014-02-06
E-polylysine Conjugates And The Use Thereof
App 20120122788 - Kuebelbeck; Armin ;   et al.
2012-05-17
Hydrophobic Modified Pres-Derived Peptides of Hepatitis B Virus (HBV) and Their Use as Vehicles for the Specific Delivery of Compounds to the Liver
App 20110027183 - Mier; Walter ;   et al.
2011-02-03
Diagnostic Agents For Positron Emission Imaging Using F-18 Radio-labeled Amino-alcohols
App 20090130020 - Lehmann; Lutz ;   et al.
2009-05-21
Polyamine-substituted ligands for use as contrast agents
App 20070202047 - Wolf; Markus ;   et al.
2007-08-30
Oligonucleotide conjugates
App 20010029035 - Eisenhut, Michael ;   et al.
2001-10-11

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed